Welcome to our dedicated page for CytomX Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on CytomX Therapeutics stock.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) is a leading oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics with its proprietary Probody® technology platform. Based in South San Francisco, CytomX leverages this platform to develop cancer immunotherapies that target clinically-validated and novel oncological targets. The unique Probody® therapeutics are designed to enhance the tumor-targeting capabilities of antibodies while minimizing toxicity in healthy tissues.
Probody® therapeutics operate by taking advantage of the unique conditions present in the tumor microenvironment, thereby improving both the efficacy and safety profiles of monoclonal antibody treatments, including cancer immunotherapies, antibody-drug conjugates (ADCs), and T-cell-recruiting bispecific antibodies. The company's innovative pipeline includes several promising candidates currently in various stages of development.
Among its recent achievements, CytomX is advancing its lead programs, CX-2051 and CX-801, into Phase 1 clinical studies. CX-2051 is an ADC that targets EpCAM-expressing tumors, including colorectal cancer, while CX-801 aims to overcome limitations associated with interferon-directed therapies. These candidates exemplify the versatility and productivity of CytomX's Probody® platform, promising significant advancements in cancer treatment.
CytomX has established strategic collaborations with industry leaders such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna to further enhance its research and development capabilities. As a result, the company is well-positioned to lead in the development of conditionally activated biologics designed for localized action within tumor microenvironments.
Financially, CytomX has made significant strides in cost control and strategic allocation of capital towards lead pipeline programs. In 2023, the company reduced its total operating expenses by $46.8 million, driven by workforce reductions and strategic pipeline prioritization. Research and development expenses decreased by $34.0 million, while general and administrative expenses decreased by $12.8 million.
For more information about CytomX and its innovative approach to cancer treatment, visit their official website at www.cytomx.com and follow them on LinkedIn and Twitter.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced the granting of stock options to nine new employees, totaling 157,200 shares at an exercise price of $4.97, matching the closing price on September 15, 2021. These options were issued under the 2019 Employment Inducement Incentive Plan to attract new talent. CytomX is focused on developing conditionally activated therapeutics for cancer treatment based on its Probody technology, with significant collaborations with major firms like AbbVie and Bristol Myers Squibb, and a portfolio featuring multiple candidates in clinical trials.
CytomX Therapeutics (Nasdaq: CTMX) announced that Sean McCarthy, D.Phil., will participate in a virtual fireside chat during the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.
The pre-recorded session will be available for on-demand viewing starting September 13 at 7:00 a.m. ET on CytomX’s website, with a 90-day archive afterwards. CytomX is developing Probody therapeutics aimed at treating cancer, focusing on minimizing toxicity while enhancing treatment efficacy.
CytomX Therapeutics (CTMX) announced the grant of stock options to seven new employees for a total of 172,600 shares at $4.81 each, reflecting the closing price on August 16, 2021. This grant, made under the 2019 Employment Inducement Incentive Plan, aims to attract new talent. CytomX, an oncology-focused biopharmaceutical firm, specializes in conditionally activated antibody therapeutics using its Probody® technology platform to target cancer effectively while minimizing toxicity. The company collaborates with major pharmaceutical partners and has a clinical pipeline advancing towards Phase 2 studies.
CytomX Therapeutics (CTMX) reported its Q2 2021 financial results, showing $16 million in revenue, consistent with Q2 2020. Cash reserves totaled $366 million, up from $316 million at year-end 2020. The company continues to advance its Probody therapeutics pipeline with ongoing Phase 2 studies for leading drug candidates CX-2009 and CX-2029. Initial data from CX-2009, impacted by COVID-19, is now expected in 2022, while data from CX-2029 is anticipated in Q4 2021. Five peer-reviewed publications in 2021 highlight CytomX's scientific advancements.
CytomX Therapeutics (Nasdaq: CTMX) announced significant findings related to its investigational drug pacmilimab (CX-072) in three peer-reviewed publications. Pacmilimab exhibited single-agent activity in advanced solid tumors, notably in metastatic triple-negative breast cancer (TNBC). It demonstrated potential for combination therapies with ipilimumab, addressing limitations of conventional immune checkpoint inhibitors. The overall objective response rate (ORR) in patients treated was 12%, with a disease control rate of 42%. Results suggest pacmilimab may provide a safer alternative with reduced toxicity.
CytomX Therapeutics (Nasdaq: CTMX) announced that CEO Sean McCarthy will participate in two upcoming virtual investor conferences. The BTIG 5th Virtual Biotechnology Conference is scheduled for August 9, 2021, at 1:00 p.m. ET, followed by the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, with a panel discussion at 1:10 p.m. ET. CytomX focuses on developing Probody therapeutics, which are designed to selectively target tumors and minimize toxicity. The company collaborates with leaders in the biotechnology sector and has a robust clinical pipeline.
CytomX Therapeutics (Nasdaq: CTMX) announced the upcoming release of its second quarter 2021 financial results on August 5, 2021, after U.S. market close. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results and provide updates on corporate developments. CytomX focuses on developing conditionally activated therapeutics utilizing its Probody® technology platform, aimed at enhancing cancer treatment efficacy while minimizing toxicity. The company collaborates with prominent firms like AbbVie and Bristol Myers Squibb on various clinical-stage assets.
CytomX Therapeutics reported positive results from the Phase 1 study of CX-2029, the first CD71-targeting antibody-drug conjugate (ADC), highlighting its well-tolerated safety profile.
The study, published in Clinical Cancer Research, involved 45 patients with advanced solid tumors, showing encouraging anti-tumor responses at doses of 2 mg/kg and higher.
The recommended Phase 2 dose is 3 mg/kg every three weeks. The ongoing Phase 2 expansion study targets various cancers, with initial results expected in Q4 2021.
CytomX Therapeutics (Nasdaq: CTMX) is set to participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 2:00 p.m. ET. Dr. Amy Peterson, chief development officer, will represent the company during this event. Investors can access a live webcast on CytomX’s website with an archived replay available for 30 days post-event. CytomX is a leader in oncology-focused therapeutics, utilizing its Probody technology to develop safer, more effective cancer treatments through conditionally activated biologics.
CytomX Therapeutics, Inc. (CTMX) reported its Q1 2021 financial results, highlighting a revenue decrease to $16 million from $49.6 million Y/Y, primarily due to reduced milestone payments. Cash reserves rose to $393.8 million, bolstered by a $108 million public offering. Key advancements include ongoing Phase 2 studies for praluzatamab ravtansine (CX-2009) and CX-2029, targeting unmet cancer needs. The company also faced delays in IND submissions for CX-2043 due to supply chain issues, while expanding collaborations with Bristol Myers Squibb and Amgen.
FAQ
What is the current stock price of CytomX Therapeutics (CTMX)?
What is the market cap of CytomX Therapeutics (CTMX)?
What is CytomX Therapeutics, Inc.?
What is the Probody® technology platform?
Which are the leading programs of CytomX?
Who are CytomX's strategic partners?
What recent financial achievements has CytomX made?
What are the benefits of Probody® therapeutics?
How does CytomX's Probody® platform contribute to cancer treatment?
Where is CytomX Therapeutics located?
What types of cancer does CX-2051 target?
How can I learn more about CytomX's latest developments?
